Nintedanib: A Review in Fibrotic Interstitial Lung Diseases

Overview

Journal Drugs

Specialty Pharmacology

Date 2021 Mar 25

PMID 33765296

Citations 47

Authors

Yvette N Lamb

Affiliations

Soon will be listed here.

Abstract

Progressive fibrosing interstitial lung diseases (ILDs) involve similar pathophysiological processes, indicating the potential for common approaches to treatment. Nintedanib (Ofev), an intracellular tyrosine kinase inhibitor (TKI) with antifibrotic properties, was one of the first drugs approved for use in idiopathic pulmonary fibrosis (IPF) and has more recently been approved for use in other chronic fibrosing ILDs with a progressive phenotype and systemic sclerosis-associated ILD (SSc-ILD). In multinational phase III trials, nintedanib significantly reduced the annual rate of decline in forced vital capacity (FVC) in adults with IPF, other progressive fibrosing ILDs and SSc-ILD. Reductions in FVC decline with nintedanib in patients with IPF and severe gas exchange impairment were comparable to those in patients with milder disease. Real-world experience in patients with IPF supports the effectiveness of nintedanib in slowing ILD progression. Nintedanib had a manageable tolerability profile in patients with fibrotic ILDs in clinical trials and real-world studies. No new safety signals have emerged from global pharmacovigilance data. Nintedanib continues to represent an important therapeutic option in patients with IPF and is the first drug to be approved for use in patients with other chronic fibrosing ILDs with a progressive phenotype or SSc-ILD, with these approvals expanding the range of fibrotic ILDs for which nintedanib can be prescribed.

Citing Articles

Baseline total lung capacity and all-cause mortality in restrictive pulmonary disorders: a meta-analysis.

Li F, Chen Y, Zhang G, Liu M, Zeng H, Dai H BMC Pulm Med. 2025; 25(1):103.

PMID: 40055715 PMC: 11889751. DOI: 10.1186/s12890-024-03425-8.

Prevention and Treatment of Peritoneal Dialysis-Associated Fibrosis with Intraperitoneal Anti-Fibrotic Therapy in Experimental Peritoneal Fibrosis.

Sun C, Hsieh Y, Lu S, Huang C Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006006 PMC: 11859390. DOI: 10.3390/ph18020188.

Novel Maleimide Linkers Based on a Piperazine Motif for Strongly Increased Aqueous Solubility.

Dijkstra M, Schueffl H, Federa A, Kast C, Unterlercher A, Keppler B ACS Omega. 2025; 10(5):5047-5063.

PMID: 39959040 PMC: 11822723. DOI: 10.1021/acsomega.4c10825.

High-density lipoprotein nanoparticles spontaneously target to damaged renal tubules and alleviate renal fibrosis by remodeling the fibrotic niches.

He S, Li X, He Y, Guo L, Dong Y, Wang L Nat Commun. 2025; 16(1):1061.

PMID: 39870661 PMC: 11772610. DOI: 10.1038/s41467-025-56223-z.

Polymeric Polylactic Acid-Glycolic Acid-Based Nanoparticles Deliver Nintedanib Across the Blood-Brain Barrier to Inhibit Glioblastoma Growth.

Dang Y, Zhao Z, Wang B, Du A, Li S, Yuan G Int J Mol Sci. 2025; 26(2).

PMID: 39859159 PMC: 11765036. DOI: 10.3390/ijms26020443.

References

Corte T, Bonella F, Crestani B, Demedts M, Richeldi L, Coeck C . Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respir Res. 2015; 16:116. PMC: 4581488. DOI: 10.1186/s12931-015-0276-5. View

Keating G . Nintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis. Drugs. 2015; 75(10):1131-40. DOI: 10.1007/s40265-015-0418-6. View

Richeldi L, Kolb M, Jouneau S, Wuyts W, Schinzel B, Stowasser S . Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. BMC Pulm Med. 2020; 20(1):3. PMC: 6951000. DOI: 10.1186/s12890-019-1030-4. View

Hayton C, Chaudhuri N . Managing Idiopathic Pulmonary Fibrosis: Which Drug for Which Patient?. Drugs Aging. 2017; 34(9):647-653. DOI: 10.1007/s40266-017-0488-0. View

Antoniou K, Markopoulou K, Tzouvelekis A, Trachalaki A, Vasarmidi E, Organtzis J . Efficacy and safety of nintedanib in a Greek multicentre idiopathic pulmonary fibrosis registry: a retrospective, observational, cohort study. ERJ Open Res. 2020; 6(1). PMC: 6983495. DOI: 10.1183/23120541.00172-2019. View

Flaherty K, Wells A, Cottin V, Devaraj A, Walsh S, Inoue Y . Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019; 381(18):1718-1727. DOI: 10.1056/NEJMoa1908681. View

Brunnemer E, Walscher J, Tenenbaum S, Hausmanns J, Schulze K, Seiter M . Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis. Respiration. 2018; 95(5):301-309. PMC: 5985741. DOI: 10.1159/000485933. View

Assassi S, Sharif R, Lasky R, McNearney T, Estrada-Y-Martin R, Draeger H . Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther. 2010; 12(5):R166. PMC: 2990992. DOI: 10.1186/ar3125. View

Wind S, Schmid U, Freiwald M, Marzin K, Lotz R, Ebner T . Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib. Clin Pharmacokinet. 2019; 58(9):1131-1147. PMC: 6719436. DOI: 10.1007/s40262-019-00766-0. View

10.

Rochwerg B, Neupane B, Zhang Y, Cuello Garcia C, Raghu G, Richeldi L . Treatment of idiopathic pulmonary fibrosis: a network meta-analysis. BMC Med. 2016; 14:18. PMC: 4741055. DOI: 10.1186/s12916-016-0558-x. View

11.

Kreuter M, Koegler H, Trampisch M, Geier S, Richeldi L . Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials. Respir Res. 2019; 20(1):71. PMC: 6458653. DOI: 10.1186/s12931-019-1037-7. View

12.

Cottin V, Wollin L, Fischer A, Quaresma M, Stowasser S, Harari S . Fibrosing interstitial lung diseases: knowns and unknowns. Eur Respir Rev. 2019; 28(151). PMC: 9489101. DOI: 10.1183/16000617.0100-2018. View

13.

Lancaster L, Crestani B, Hernandez P, Inoue Y, Wachtlin D, Loaiza L . Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials. BMJ Open Respir Res. 2019; 6(1):e000397. PMC: 6530503. DOI: 10.1136/bmjresp-2018-000397. View

14.

Crestani B, Huggins J, Kaye M, Costabel U, Glaspole I, Ogura T . Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. Lancet Respir Med. 2018; 7(1):60-68. DOI: 10.1016/S2213-2600(18)30339-4. View

15.

Kolb M, Richeldi L, Behr J, Maher T, Tang W, Stowasser S . Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax. 2016; 72(4):340-346. PMC: 5520269. DOI: 10.1136/thoraxjnl-2016-208710. View

16.

Highland K, Distler O, Kuwana M, Allanore Y, Assassi S, Azuma A . Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. Lancet Respir Med. 2021; 9(1):96-106. DOI: 10.1016/S2213-2600(20)30330-1. View

17.

Flaherty K, Fell C, Huggins J, Nunes H, Sussman R, Valenzuela C . Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis. Eur Respir J. 2018; 52(2). PMC: 6092682. DOI: 10.1183/13993003.00230-2018. View

18.

Lasky J, Criner G, Lazarus H, Kohlbrenner V, Bender S, Richeldi L . Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data. Adv Ther. 2020; 37(10):4209-4219. DOI: 10.1007/s12325-020-01452-5. View

19.

Brown K, Flaherty K, Cottin V, Raghu G, Inoue Y, Azuma A . Lung function outcomes in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. Respir Med. 2019; 146:42-48. DOI: 10.1016/j.rmed.2018.11.012. View

20.

Marzin K, Kretschmar G, Luedtke D, Kraemer S, Kuelzer R, Schlenker-Herceg R . Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment. J Clin Pharmacol. 2017; 58(3):357-363. PMC: 5836871. DOI: 10.1002/jcph.1025. View